Susan E. O'Reilly
University of British Columbia
35 Papers
1.4K Citations
Susan E. O'Reilly is an academic researcher from University of British Columbia. The author has contributed to research in topics: Medicine & Chemotherapy. The author has an hindex of 24, co-authored 35 publications. Previous affiliations of Susan E. O'Reilly include National Institutes of Health & Sanford-Burnham Institute for Medical Research.
Chat about Author
Papers
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
Laurie H. Sehn,Jane Donaldson,Mukesh Chhanabhai,Catherine Fitzgerald,Karamjit Gill,Richard Klasa,Nicol Macpherson,Susan E. O'Reilly,John J. Spinelli,Judy Sutherland,Kenneth S. Wilson,Randy D. Gascoyne,Joseph M. Connors +12 more
- 01 Jan 2005
TL;DR: The addition of rituximab to CHOP chemotherapy has resulted in a dramatic improvement in outcome for DLBCL patients of all ages in the province of BC.
815
The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer
Stephen Chia,Caroline Speers,Yulia D'yachkova,Anna Kang,Suzanne Malfair-Taylor,Jeff Barnett,Andy Coldman,Karen A. Gelmon,Susan E. O'Reilly,Ivo A. Olivotto +9 more
TL;DR: This study characterized the use and assessed the impact on survival of population‐based access to new agents for the treatment of MBC.
464
Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Joseph M. Connors,Paul Klimo,Grenfell Adams,Bruce F. Burns,Ian Cooper,Ralph M. Meyer,Susan E. O'Reilly,J. Pater,Ian Quirt,Anna Sadura,Chaim Shustik,J. Skillings,Simon Sutcliffe,Shailendra Verma,Sam Yoshida,Benny Zee +15 more
TL;DR: MOPp/ABV hybrid and alternating MOPP/ABVD regimens are equally effective for patients with advanced Hodgkin's disease.
159
Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988
Andreas Lohri,Michael L. Barnett,R N Fairey,Susan E. O'Reilly,Gordon L. Phillips,Donna E. Reece,Nicholas Voss,Joseph M. Connors +7 more
TL;DR: Reports on salvage treatments for Hodgkin's disease in first relapse after primary chemotherapy should include data on the proportion of patients having stage IV disease at diagnosis, B symptoms at relapse, and a time from primary treatment to relapse of less than 1 year.
127
Brief Chemotherapy and Involved-Region Irradiation for Limited-Stage Diffuse Large-Cell Lymphoma: An 18-Year Experience From the British Columbia Cancer Agency
Tamara Shenkier,Nicholas Voss,R N Fairey,Randy D. Gascoyne,Paul Hoskins,Richard Klasa,Paul Klimo,Susan E. O'Reilly,Simon Sutcliffe,Joseph M. Connors +9 more
TL;DR: Long-term outcome with three cycles of doxorubicin-based chemotherapy and IRRT confirms that this is a successful approach for the majority of patients with limited-stage DLCL, and subgroups with worse prognoses can be identified and offered alternative treatment approaches.
116